ClinicalTrials.Veeva

Menu
T

Tampere University Hospital | Tampere Heart Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Interferon
BI 1015550
Carboplatin
Nintedanib
Venetoclax
Upadacitinib
Trastuzumab
Doxorubicin
ABT-494

Parent organization

This site is a part of Tampere University Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

42 of 379 total trials

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (BANTAM-01)

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver canc...

Enrolling
Hepatocellular Carcinoma
Drug: BAY 3547926
Drug: BAY 3547922

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1015550

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: tafasitamab
Drug: placebo

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in e...

Enrolling
DLBCL
Diffuse Large B Cell Lymphoma
Drug: R-pola-mini-CHP
Drug: R-mini-CHOP

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Active, not recruiting
Solid Tumors
Drug: Bemarituzumab

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combin...

Active, not recruiting
Advanced Solid Tumors Cancer
Drug: Nivolumab
Drug: Osimertinib

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Azacitidine

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodyspla...

Active, not recruiting
Relapsed/Refractory AML
Myelodysplastic Syndromes
Drug: Venetoclax
Drug: Azacitidine

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took pa...

Active, not recruiting
Lung Diseases, Interstitial
Drug: Nintedanib (Ofev®)

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling
Metastatic Breast Cancer
Drug: Inavolisib
Drug: Optional Endocrine Therapy of Investigator's Choice

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatmen...

Active, not recruiting
Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Drug: Gemcitabine
Drug: Cisplatin

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal g...

Enrolling
Breast Cancer
Procedure: Tumor Tissue and Blood Draw

Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants w...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: BAY3546828

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).Acalabrutinib...

Active, not recruiting
MCL
Mantle Cell Lymphoma
Drug: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma

Trial sponsors

T
H
T
Boehringer Ingelheim logo
T
U
Roche logo
AbbVie logo
O
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems